Rephine in the Spotlight

Explore exclusive insights from Rephine’s thought leaders and industry experts, featured in prominent pharmaceutical online blogs and publications.

Topic

Innovation, Alliances, and the Environment: 2024 Priorities for Drug Manufacturers

Explore the evolving landscape of 2023’s key trends—adaptability, global collaboration, supply chain innovation, and mRNA technologies—anticipated to accelerate in 2024, as highlighted by Rephine’s Dr. Eduard Cayón in the European Pharmaceutical Manufacturer. Expect a surge in innovation, intensified focus on unmet clinical needs, commercial alliances, and the pursuit of Net Zero objectives.

Originally posted on December 1, 2023

A Year On: Sterile Medicinal Products Regulations

Rephine’s GxP Expert and Pharmaceutical Senior Consultant, Anna Cluet, sheds light on the impact of the new EU GMP Annex 1 requirements in Pharmaceutical Manufacturer and Packing Sourcer. Discover practical insights into how companies are navigating compliance challenges and implementing effective contamination strategies and quality risk management in the realm of sterile medicinal product manufacturing.

Originally posted on October 6, 2023

Shoring up medicinal supply: new Regulatory expectations

Discover practical insights from Juan Torrijos Lopez, GMP consultant at Rephine, in European Pharmaceutical Manufacturer. Gain valuable guidance on responding to evolving expectations in pharmaceutical manufacturing amidst global challenges, ensuring continuous and reliable drug supplies for patients worldwide.

Originally posted on September 1, 2023

Emerging Quality considerations across the global Life Sciences supply chain

Explore the future of pharmaceutical quality with Dr. Eduard Cayón from Rephine in International Pharma. Gain insights into the evolving landscape of Life Sciences innovation and regulatory shifts, focusing on ensuring consistent standards in manufacturing processes, systems, and supply-chain partnerships amid the push for process digitalisation and automation.

Originally posted on February 10, 2023

Emerging Quality considerations across the global Life Sciences supply chain

Explore the future of pharmaceutical quality with Dr. Eduard Cayón from Rephine in European Pharmaceutical Manufacturer. Gain insights into the evolving landscape of Life Sciences innovation and regulatory shifts, focusing on ensuring consistent standards in manufacturing processes, systems, and supply-chain partnerships amid the push for process digitalisation and automation.

Originally posted on February 2, 2023

Opening Up Opportunities in 2023

Discover the future of the bio/pharmaceutical industry with Rephine’s CEO, Adam Sherlock, in this exclusive article with Pharm Times. Gain insights into the industry’s resilience amid global disruptions, the ascent of digital health, expanding AI applications, and the progressive shift towards biological products. Dive into the evolving landscape with Sherlock’s reflections on the challenges of 2022 and the prospects for 2023.

Originally posted on January 3, 2023

Practical Steps to Prepare for EU GMP Annex 1 Provisions

Explore the latest insights from Rephine’s GxP Expert and Pharmaceutical Senior Consultant, Anna Cluet, in the Journal of mHealth. Navigate the significant and wide-ranging updates to the EU GMP Annex 1 requirements, designed to enhance sterility confidence in medicinal products. Gain practical steps from Cluet on addressing these requirements, as she unpacks the key areas and offers advice for compliance before the August 2023 deadline.

Originally posted on December 21, 2022

Innovation in pharma manufacturing as paradigms shift and biotech & personalised therapies move through clinical trials at pace

Explore the evolving landscape of pharmaceutical manufacturing with Dr. Eduard Cayón, Chief Scientific Officer at Rephine, as featured in American Pharm Outsourcing. Delve into the shift towards biotech and personalized therapies, discovering how it optimises new ways of working. Gain insights into the impact on Quality monitoring, management, and assurance as the industry transitions from lab-based research to full-scale production.

Originally posted on November 1, 2022

Will remote pharma GMP auditing endure post-pandemic?

Discover the future of GMP auditing with Alasdair Lackie, VP Audit Services at Rephine, in Pharma Tech Focus. Explore the potential permanence of remote auditing post-pandemic and the varied perspectives within the industry on its feasibility in verifying manufacturing and distribution standards of supply-chain partners.

Originally posted on March 15, 2022
Newsletter